• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Genfit

parachute sun mountain sunrise
Biotech

Yet another CDER leadership shake-up—Chutes & Ladders

Yet another CDER leadership shake-up. Ovid taps new CMO. Altimmune elevates experienced new CEO.
Darren Incorvaia , Zoey Becker Dec 5, 2025 8:30am
Make a delay and accumulation of outstanding tasks Full stop

Genfit ends liver failure program over phase 2 safety signal

Sep 22, 2025 5:14am
speedometer accelerate fast speed push

Genfit moves to jump-start enrollment in liver failure trial

Sep 20, 2024 9:47am
liver NASH NAFLD

Ipsen posts mixed liver disease data on Intercept, CymaBay rival

Nov 14, 2023 5:55am
Liver doctor holding liver

Ipsen, Genfit report phase 3 rare liver disease success

Jun 30, 2023 6:15am
Liver disease

Genfit licenses liver failure drug from Seal Rock in $107M deal

Jun 1, 2023 8:25am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings